MedPath

Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair

Completed
Conditions
Abdominal Aortic Aneurysms (AAA)
Endovascular Aneurysm Repair (EVAR)
Registration Number
NCT06876727
Lead Sponsor
Samsung Medical Center
Brief Summary

This study was a target trial emulation using the National Health Claims database established by the Korean National Health Insurance Service (K-NHIS). 8,325 patients were included.

Detailed Description

Among these patients, any patients who were prescribed SAPT or DAPT at the date of discharge from the index hospitalization for standard EVAR were defined as being in the SAPT group (N=4,162) and the DAPT group (N=4,163), respectively.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
8325
Inclusion Criteria
  • All patients who underwent EVAR for AAA and were successfully discharged
Exclusion Criteria
  • Patients who had experienced a myocardial infarction
  • Patients who had experienced a stroke
  • Patients who had experienced percutaneous coronary intervention
  • Patients who had history of peripheral disease
  • Patients who had major bleeding event within 1 year of admission
  • Those prescribed non-vitamin K antagonist oral anticoagulant or warfarin
  • Patients who did not prescribe any antiplatelet therapy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Major adverse cardiac and cerebrovascular events (MACCE)1 year after EVAR

composite of all-cause death, myocardial infarction (MI), or ischemic stroke

Major or clinically relevant non-major bleeding1 year after EVAR

Diagnostic codes in the primary or secondary position and transfusion receipt

Re-intervention or surgery for AAAs1 year after EVAR

Re-intervention or surgery for AAAs

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath